Sepsis syndrome is characterized by a systemic inflammatory response to infection potentially leading to acute organ failure and rapid decline to death. Polyclonal intravenous immune globulin, a blood product derived from human donor blood, in addition to antiinfective activities, also exerts a broad antiinflammatory and immunomodulating effect. Intravenous immunoglobulin (IVIg) has been proposed as adjuvant therapy for sepsis even though the clinical studies demonstrating their efficacy and safety are relatively small. Several systematic reviews and meta-analyses of intravenous immunoglobulin treatment in sepsis have been performed. As a result of heterogeneity across studies and inconsistencies in results, the majority have concluded that more evidence, coming from large, well-conducted randomized controlled trials (RCTs), is required. Moreover the appropriate timing of administration and the identification of specific clinical settings represent a key factor to maximizing their beneficial effect. The authors, in this revision, review the basic mechanisms of action of IVIg, the rationale for their use, and their clinical applications. (C) 2014 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.

Polyclonal intravenous immunoglobulin: An important additional strategy in sepsis? / DI ROSA, Roberta; M., Pietrosanti; Luzi, Giuseppe; S., Salemi; D'Amelio, Raffaele. - In: EUROPEAN JOURNAL OF INTERNAL MEDICINE. - ISSN 0953-6205. - STAMPA. - 25:6(2014), pp. 511-516. [10.1016/j.ejim.2014.05.002]

Polyclonal intravenous immunoglobulin: An important additional strategy in sepsis?

DI ROSA, Roberta;LUZI, Giuseppe;D'AMELIO, Raffaele
2014

Abstract

Sepsis syndrome is characterized by a systemic inflammatory response to infection potentially leading to acute organ failure and rapid decline to death. Polyclonal intravenous immune globulin, a blood product derived from human donor blood, in addition to antiinfective activities, also exerts a broad antiinflammatory and immunomodulating effect. Intravenous immunoglobulin (IVIg) has been proposed as adjuvant therapy for sepsis even though the clinical studies demonstrating their efficacy and safety are relatively small. Several systematic reviews and meta-analyses of intravenous immunoglobulin treatment in sepsis have been performed. As a result of heterogeneity across studies and inconsistencies in results, the majority have concluded that more evidence, coming from large, well-conducted randomized controlled trials (RCTs), is required. Moreover the appropriate timing of administration and the identification of specific clinical settings represent a key factor to maximizing their beneficial effect. The authors, in this revision, review the basic mechanisms of action of IVIg, the rationale for their use, and their clinical applications. (C) 2014 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.
2014
sepsis; septic shock; immunomodulation; severe sepsis; neonatal sepsis; intravenous immunoglobulin
01 Pubblicazione su rivista::01a Articolo in rivista
Polyclonal intravenous immunoglobulin: An important additional strategy in sepsis? / DI ROSA, Roberta; M., Pietrosanti; Luzi, Giuseppe; S., Salemi; D'Amelio, Raffaele. - In: EUROPEAN JOURNAL OF INTERNAL MEDICINE. - ISSN 0953-6205. - STAMPA. - 25:6(2014), pp. 511-516. [10.1016/j.ejim.2014.05.002]
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/618223
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 10
  • Scopus 24
  • ???jsp.display-item.citation.isi??? 20
social impact